December 2, 2021

Innovative approaches in multiple myeloma that focus on cellular therapies offer hope to patients with multiple myeloma.

The most effective treatment strategy—adjuvant, neoadjuvant, or some combination of adjuvant plus neoadjuvant regimens— remains unclear. Ongoing trials are dedicated to defining the best sequence of treatment.

Two oncologists give their expert take on KRAS- and EGFR-mutant non–small cell lung cancer.

The improvement in detection and treatment associated with PSMA cannot be overstated, with many investigators describing the advancement as a global practice changer.

In light of the continued risks of COVID-19, especially for immunocompromised patients and those with cancer, physicians and guidelines have recommended vaccination including booster shots as soon as possible for all patients with cancer.

In using the biomarker approach to the treatment of triple-negative breast cancer, the challenge for the clinician is prioritizing the available treatment options based on the National Comprehensive Cancer Network guidelines for breast cancer, which focus on active agents, preferred single-agent chemotherapy approaches, and doublet options for certain patients at high risk.

The social determinants of health disparities have expanded the definition of personalized medicine, Karen Winkfield, MD, PhD, said.

With the rapid advancement of CAR T, there is no doubt that many patients in the future will reap the benefits.

RP-3500 was shown to have a promising safety profile and efficacy in a first-in-human biomarker-driven phase 1/2 study.